drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00451 | DB01364 | 542 | 22 | [
"DDInter1064",
"DDInter650"
] | Levothyroxine | Ephedrine | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
542,
24,
22
]
],
[
[
542,
63,
80
],
[
80,
24,
22
]
],
[
[
542,
24,
1529
],
[
1529,
63,
22
]
],
[
[
542,
24,
280
],
[
280,
1,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine ... |
DB00059 | DB06663 | 1,560 | 1,154 | [
"DDInter1404",
"DDInter1398"
] | Pegaspargase | Pasireotide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
1560,
24,
1154
]
],
[
[
1560,
24,
1247
],
[
1247,
23,
1154
]
],
[
[
1560,
24,
1385
],
[
1385,
63,
1154
]
],
[
[
1560,
24,
663
],
[
663... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Semagl... |
DB00581 | DB04844 | 355 | 843 | [
"DDInter1018",
"DDInter1778"
] | Lactulose | Tetrabenazine | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
355,
24,
843
]
],
[
[
355,
21,
28809
],
[
28809,
60,
843
]
],
[
[
355,
63,
1555
],
[
1555,
24,
843
]
],
[
[
355,
23,
286
],
[
286,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cau... | Lactulose (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Tetrabenazine (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tetr... |
DB00047 | DB01284 | 176 | 1,042 | [
"DDInter932",
"DDInter1782"
] | Insulin glargine | Tetracosactide | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
176,
24,
1042
]
],
[
[
176,
24,
455
],
[
455,
23,
1042
]
],
[
[
176,
24,
659
],
[
659,
62,
1042
]
],
[
[
176,
24,
461
],
[
461,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Vilante... |
DB00015 | DB00278 | 582 | 291 | [
"DDInter1585",
"DDInter117"
] | Reteplase | Argatroban | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Major | 2 | [
[
[
582,
25,
291
]
],
[
[
582,
23,
297
],
[
297,
62,
291
]
],
[
[
582,
24,
972
],
[
972,
63,
291
]
],
[
[
582,
24,
1230
],
[
1230,
2... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} ... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Argatroban
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicy... |
DB00209 | DB00999 | 352 | 504 | [
"DDInter1886",
"DDInter883"
] | Trospium | Hydrochlorothiazide | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Minor | 0 | [
[
[
352,
23,
504
]
],
[
[
352,
23,
178
],
[
178,
1,
504
]
],
[
[
352,
23,
323
],
[
323,
40,
504
]
],
[
[
352,
21,
28779
],
[
28779,
... | [
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
],
[... | Trospium may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Trospium may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles... |
DB01068 | DB12130 | 1,565 | 1,017 | [
"DDInter411",
"DDInter1094"
] | Clonazepam | Lorlatinib | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1565,
24,
1017
]
],
[
[
1565,
63,
608
],
[
608,
23,
1017
]
],
[
[
1565,
1,
686
],
[
686,
24,
1017
]
],
[
[
1565,
63,
629
],
[
629,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Clonazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerb... |
DB00489 | DB00981 | 17 | 1,528 | [
"DDInter1704",
"DDInter1462"
] | Sotalol | Physostigmine | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
17,
24,
1528
]
],
[
[
17,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
17,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
17,
24,
543
],
[
543,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by... | Sotalol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigm... |
DB01172 | DB01329 | 416 | 1,458 | [
"DDInter1004",
"DDInter322"
] | Kanamycin | Cefoperazone | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against <i>Pseudomonas</i> infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, per... | Moderate | 1 | [
[
[
416,
24,
1458
]
],
[
[
416,
63,
277
],
[
277,
1,
1458
]
],
[
[
416,
24,
1402
],
[
1402,
40,
1458
]
],
[
[
416,
24,
1227
],
[
1227,
... | [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoperazone"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[
... | Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefoperazone (Compound)
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefotetan and Cefotetan (Compound) resembles Cefoperazone (Compound... |
DB00332 | DB08897 | 1,089 | 1,429 | [
"DDInter970",
"DDInter22"
] | Ipratropium | Aclidinium | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
1089,
24,
1429
]
],
[
[
1089,
63,
352
],
[
352,
24,
1429
]
],
[
[
1089,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
1089,
6,
4304
],
[
4304,... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzo... |
DB06207 | DB08820 | 910 | 1,478 | [
"DDInter1667",
"DDInter997"
] | Silodosin | Ivacaftor | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
910,
24,
1478
]
],
[
[
910,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
910,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
910,
24,
1040
],
[
1040,... | [
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Silodosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Silodosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Silodosin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib ... |
DB00719 | DB01618 | 1,219 | 776 | [
"DDInter149",
"DDInter1239"
] | Azatadine | Molindone | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
1219,
24,
776
]
],
[
[
1219,
24,
100
],
[
100,
24,
776
]
],
[
[
1219,
24,
1511
],
[
1511,
63,
776
]
],
[
[
1219,
63,
19
],
[
19,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate an... |
DB00331 | DB00554 | 1,645 | 1,027 | [
"DDInter1164",
"DDInter1478"
] | Metformin | Piroxicam | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Moderate | 1 | [
[
[
1645,
24,
1027
]
],
[
[
1645,
24,
1171
],
[
1171,
1,
1027
]
],
[
[
1645,
24,
1194
],
[
1194,
62,
1027
]
],
[
[
1645,
24,
752
],
[
752,... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Piroxicam (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit cli... |
DB00275 | DB01168 | 217 | 1,053 | [
"DDInter1330",
"DDInter1526"
] | Olmesartan | Procarbazine | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
217,
24,
1053
]
],
[
[
217,
24,
848
],
[
848,
40,
1053
]
],
[
[
217,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
217,
24,
104
],
[
104,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Olmesartan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Olmesartan may cause a moderate interaction ... |
DB01284 | DB06168 | 1,042 | 1,531 | [
"DDInter1782",
"DDInter281"
] | Tetracosactide | Canakinumab | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1042,
24,
1531
]
],
[
[
1042,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
1042,
63,
1031
],
[
1031,
24,
1531
]
],
[
[
1042,
24,
1683
],
[
16... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purifie... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Tetracosactide may cause a moderate interaction tha... |
DB04845 | DB04868 | 309 | 478 | [
"DDInter1001",
"DDInter1293"
] | Ixabepilone | Nilotinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
309,
24,
478
]
],
[
[
309,
24,
1468
],
[
1468,
63,
478
]
],
[
[
309,
6,
8374
],
[
8374,
45,
478
]
],
[
[
309,
21,
29563
],
[
29563,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ixabepilone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Ixabepilone (Compoun... |
DB00661 | DB01268 | 122 | 1,151 | [
"DDInter1928",
"DDInter1731"
] | Verapamil | Sunitinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
122,
24,
1151
]
],
[
[
122,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
122,
21,
28653
],
[
28653,
60,
1151
]
],
[
[
122,
25,
1250
],
[
1250,... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Verapamil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Verapamil (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Sunitinib (Compound)
Verapamil may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a m... |
DB00030 | DB00477 | 1,685 | 216 | [
"DDInter934",
"DDInter363"
] | Insulin human | Chlorpromazine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1685,
24,
216
]
],
[
[
1685,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1685,
24,
684
],
[
684,
40,
216
]
],
[
[
1685,
24,
417
],
[
417,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resemble... |
DB00289 | DB00694 | 847 | 51 | [
"DDInter132",
"DDInter485"
] | Atomoxetine | Daunorubicin | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
847,
24,
51
]
],
[
[
847,
6,
8374
],
[
8374,
45,
51
]
],
[
[
847,
18,
3741
],
[
3741,
57,
51
]
],
[
[
847,
21,
28644
],
[
28644,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Daunorubicin (Compound)
Atomoxetine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Daunorubicin (Compound)
Atomoxetine (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Daunorubicin (Compoun... |
DB00188 | DB01098 | 168 | 14 | [
"DDInter222",
"DDInter1622"
] | Bortezomib | Rosuvastatin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
168,
24,
14
]
],
[
[
168,
24,
671
],
[
671,
24,
14
]
],
[
[
168,
6,
8374
],
[
8374,
45,
14
]
],
[
[
168,
7,
16740
],
[
16740,
45... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Bortezomib (... |
DB01165 | DB08938 | 1,539 | 1,384 | [
"DDInter1325",
"DDInter1112"
] | Ofloxacin | Magaldrate | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1539,
24,
1384
]
],
[
[
1539,
64,
167
],
[
167,
23,
1384
]
],
[
[
1539,
25,
1220
],
[
1220,
23,
1384
]
],
[
[
1539,
63,
401
],
[
401,
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocor... | Ofloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Ofloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a min... |
DB06589 | DB10316 | 1,250 | 334 | [
"DDInter1400",
"DDInter1248"
] | Pazopanib | Mumps virus strain B level jeryl lynn live antigen | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1250,
25,
334
]
],
[
[
1250,
63,
617
],
[
617,
24,
334
]
],
[
[
1250,
24,
594
],
[
594,
25,
334
]
],
[
[
1250,
64,
1057
],
[
1057,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bude... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Pazopanib may cause a moderate interaction that could exacerbate diseases... |
DB00377 | DB01259 | 1,494 | 392 | [
"DDInter1382",
"DDInter1024"
] | Palonosetron | Lapatinib | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1494,
24,
392
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
392
]
],
[
[
1494,
21,
28688
],
[
28688,
60,
392
]
],
[
[
1494,
24,
479
],
[
479,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Palonosetron (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and D... |
DB01169 | DB11057 | 57 | 720 | [
"DDInter120",
"DDInter1223"
] | Arsenic trioxide | Mineral oil | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
57,
24,
720
]
],
[
[
57,
25,
927
],
[
927,
63,
720
]
],
[
[
57,
25,
1151
],
[
1151,
24,
720
]
],
[
[
57,
64,
758
],
[
758,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
... | Arsenic trioxide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Arsenic trioxide may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a ... |
DB06404 | DB06710 | 1,514 | 1,546 | [
"DDInter869",
"DDInter1193"
] | Human C1-esterase inhibitor | Methyltestosterone | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and... | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Moderate | 1 | [
[
[
1514,
24,
1546
]
],
[
[
1514,
63,
1581
],
[
1581,
1,
1546
]
],
[
[
1514,
63,
984
],
[
984,
40,
1546
]
],
[
[
1514,
24,
1687
],
[
1687,... | [
[
[
"Human C1-esterase inhibitor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
]
],
[
[
"Human C1-esterase inhibitor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wit... | Human C1-esterase inhibitor may cause a moderate interaction that could exacerbate diseases when taken with Testolactone and Testolactone (Compound) resembles Methyltestosterone (Compound)
Human C1-esterase inhibitor may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Co... |
DB00668 | DB01255 | 874 | 633 | [
"DDInter652",
"DDInter1078"
] | Epinephrine | Lisdexamfetamine | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
874,
24,
633
]
],
[
[
874,
24,
551
],
[
551,
1,
633
]
],
[
[
874,
63,
80
],
[
80,
40,
633
]
],
[
[
874,
64,
1523
],
[
1523,
40,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfeta... |
DB01144 | DB09082 | 1,326 | 659 | [
"DDInter540",
"DDInter1934"
] | Diclofenamide | Vilanterol | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1326,
24,
659
]
],
[
[
1326,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1326,
63,
891
],
[
891,
23,
659
]
],
[
[
1326,
24,
1296
],
[
1296,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolon... |
DB00393 | DB01168 | 854 | 1,053 | [
"DDInter1295",
"DDInter1526"
] | Nimodipine | Procarbazine | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
854,
24,
1053
]
],
[
[
854,
24,
848
],
[
848,
40,
1053
]
],
[
[
854,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
854,
24,
104
],
[
104,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Nimodipine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Nimodipine may cause a moderate interaction ... |
DB00810 | DB01069 | 456 | 401 | [
"DDInter211",
"DDInter1533"
] | Biperiden | Promethazine | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
456,
24,
401
]
],
[
[
456,
24,
1264
],
[
1264,
63,
401
]
],
[
[
456,
24,
104
],
[
104,
24,
401
]
],
[
[
456,
6,
4304
],
[
4304,
... | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazi... |
DB00381 | DB06605 | 376 | 1,409 | [
"DDInter79",
"DDInter108"
] | Amlodipine | Apixaban | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
376,
24,
1409
]
],
[
[
376,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
376,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
376,
24,
1670
],
[
1670,... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Amlodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Amlodipine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Amlodipine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglu... |
DB01254 | DB09083 | 1,213 | 880 | [
"DDInter484",
"DDInter996"
] | Dasatinib | Ivabradine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1213,
25,
880
]
],
[
[
1213,
63,
480
],
[
480,
24,
880
]
],
[
[
1213,
24,
1478
],
[
1478,
24,
880
]
],
[
[
1213,
24,
159
],
[
159,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor... |
DB00486 | DB00532 | 1,614 | 208 | [
"DDInter1253",
"DDInter1152"
] | Nabilone | Mephenytoin | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
1614,
24,
208
]
],
[
[
1614,
63,
1242
],
[
1242,
24,
208
]
],
[
[
1614,
24,
1219
],
[
1219,
63,
208
]
],
[
[
1614,
40,
530
],
[
530,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine ... |
DB11799 | DB11828 | 627 | 1,406 | [
"DDInter205",
"DDInter1281"
] | Bictegravir | Neratinib | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
627,
24,
1406
]
],
[
[
627,
63,
392
],
[
392,
24,
1406
]
],
[
[
627,
64,
1384
],
[
1384,
24,
1406
]
],
[
[
627,
24,
1619
],
[
1619,
... | [
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bictegravir may lead to a major life threatening interaction when taken with Magaldrate and Magaldrate may cause a... |
DB01041 | DB01263 | 770 | 859 | [
"DDInter1789",
"DDInter1494"
] | Thalidomide | Posaconazole | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
770,
24,
859
]
],
[
[
770,
21,
30178
],
[
30178,
60,
859
]
],
[
[
770,
63,
112
],
[
112,
23,
859
]
],
[
[
770,
64,
482
],
[
482,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Neck stiffness"
],
[
"Neck stiffness",
"{u} (Side E... | Thalidomide (Compound) causes Neck stiffness (Side Effect) and Neck stiffness (Side Effect) is caused by Posaconazole (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when ... |
DB00939 | DB11921 | 1,338 | 1,019 | [
"DDInter1135",
"DDInter492"
] | Meclofenamic acid | Deflazacort | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1338,
24,
1019
]
],
[
[
1338,
24,
959
],
[
959,
24,
1019
]
],
[
[
1338,
64,
629
],
[
629,
24,
1019
]
],
[
[
1338,
74,
1512
],
[
1512,
... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Meclofenamic acid may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus... |
DB00620 | DB09045 | 175 | 52 | [
"DDInter1855",
"DDInter607"
] | Triamcinolone | Dulaglutide | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
175,
24,
52
]
],
[
[
175,
40,
1103
],
[
1103,
23,
52
]
],
[
[
175,
24,
170
],
[
170,
23,
52
]
],
[
[
175,
25,
609
],
[
609,
24,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Triamcinolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that c... |
DB00533 | DB01099 | 1,416 | 1,272 | [
"DDInter1613",
"DDInter744"
] | Rofecoxib | Flucytosine | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
1416,
24,
1272
]
],
[
[
1416,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
1416,
24,
712
],
[
712,
63,
1272
]
],
[
[
1416,
63,
1555
],
[
1555... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Ols... |
DB01064 | DB04844 | 1,148 | 843 | [
"DDInter987",
"DDInter1778"
] | Isoprenaline | Tetrabenazine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1148,
24,
843
]
],
[
[
1148,
21,
28698
],
[
28698,
60,
843
]
],
[
[
1148,
63,
1555
],
[
1555,
24,
843
]
],
[
[
1148,
24,
823
],
[
823,... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is... | Isoprenaline (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00006 | DB00580 | 942 | 311 | [
"DDInter217",
"DDInter1910"
] | Bivalirudin | Valdecoxib | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
942,
24,
311
]
],
[
[
942,
24,
366
],
[
366,
24,
311
]
],
[
[
942,
25,
500
],
[
500,
63,
311
]
],
[
[
942,
25,
582
],
[
582,
24,... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eptifibatide"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Bivalirudin may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may ... |
DB00468 | DB09420 | 1,424 | 1,074 | [
"DDInter1557",
"DDInter953"
] | Quinine | Iodide I-123 | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1424,
24,
1074
]
],
[
[
1424,
24,
126
],
[
126,
24,
1074
]
],
[
[
1424,
63,
10
],
[
10,
24,
1074
]
],
[
[
1424,
23,
1247
],
[
1247,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"W... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause... |
DB00486 | DB01452 | 1,614 | 993 | [
"DDInter1253",
"DDInter532"
] | Nabilone | Diamorphine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
1614,
24,
993
]
],
[
[
1614,
63,
421
],
[
421,
40,
993
]
],
[
[
1614,
63,
475
],
[
475,
25,
993
]
],
[
[
1614,
24,
1637
],
[
1637,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interac... |
DB00501 | DB01259 | 752 | 392 | [
"DDInter380",
"DDInter1024"
] | Cimetidine | Lapatinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
752,
24,
392
]
],
[
[
752,
6,
4973
],
[
4973,
45,
392
]
],
[
[
752,
21,
29539
],
[
29539,
60,
392
]
],
[
[
752,
23,
271
],
[
271,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Cimetidine (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Lapatinib (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Mirabegron and ... |
DB00790 | DB00959 | 664 | 1,486 | [
"DDInter1431",
"DDInter1191"
] | Perindopril | Methylprednisolone | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
664,
24,
1486
]
],
[
[
664,
63,
175
],
[
175,
40,
1486
]
],
[
[
664,
63,
167
],
[
167,
1,
1486
]
],
[
[
664,
24,
1220
],
[
1220,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resemble... |
DB01244 | DB09080 | 762 | 144 | [
"DDInter192",
"DDInter1331"
] | Bepridil | Olodaterol | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
762,
24,
144
]
],
[
[
762,
25,
1011
],
[
1011,
24,
144
]
],
[
[
762,
64,
11
],
[
11,
24,
144
]
],
[
[
762,
25,
823
],
[
823,
63,... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
... | Bepridil may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Bepridil may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interact... |
DB00146 | DB00169 | 160 | 386 | [
"DDInter265",
"DDInter367"
] | Calcifediol | Cholecalciferol | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight . Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant... | Major | 2 | [
[
[
160,
36,
386
]
],
[
[
160,
40,
11418
],
[
11418,
1,
386
]
],
[
[
160,
25,
1041
],
[
1041,
64,
386
]
],
[
[
160,
6,
3237
],
[
3237,
... | [
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
]
],
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound)",
"Alfacalcidol"
],
[
"Alfac... | Calcifediol (Compound) resembles Cholecalciferol (Compound) and
Calcifediol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Cholecalciferol (Compound)
Calcifediol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life th... |
DB00637 | DB00640 | 1,557 | 1,585 | [
"DDInter128",
"DDInter31"
] | Astemizole | Adenosine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Major | 2 | [
[
[
1557,
25,
1585
]
],
[
[
1557,
18,
2183
],
[
2183,
57,
1585
]
],
[
[
1557,
24,
578
],
[
578,
62,
1585
]
],
[
[
1557,
24,
477
],
[
477,
... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
],
[
[
"Astemizole",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Astemizole (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Adenosine (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Adenosine
Astemizo... |
DB01067 | DB01175 | 959 | 318 | [
"DDInter826",
"DDInter672"
] | Glipizide | Escitalopram | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
959,
24,
318
]
],
[
[
959,
63,
1230
],
[
1230,
1,
318
]
],
[
[
959,
6,
8374
],
[
8374,
45,
318
]
],
[
[
959,
21,
28750
],
[
28750,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Glipizide (Compound) causes Abdominal discomfort (Side Effect) a... |
DB01403 | DB04951 | 9 | 187 | [
"DDInter1175",
"DDInter1477"
] | Methotrimeprazine | Pirfenidone | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
9,
24,
187
]
],
[
[
9,
25,
1670
],
[
1670,
63,
187
]
],
[
[
9,
63,
92
],
[
92,
24,
187
]
],
[
[
9,
64,
702
],
[
702,
24,
1... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Methotrimeprazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
... | Methotrimeprazine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Metho... |
DB05015 | DB08827 | 1,077 | 990 | [
"DDInter174",
"DDInter1085"
] | Belinostat | Lomitapide | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1077,
25,
990
]
],
[
[
1077,
24,
1362
],
[
1362,
63,
990
]
],
[
[
1077,
63,
869
],
[
869,
24,
990
]
],
[
[
1077,
63,
79
],
[
79,
... | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan m... |
DB00250 | DB01235 | 10 | 1,191 | [
"DDInter475",
"DDInter1054"
] | Dapsone | Levodopa | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
10,
24,
1191
]
],
[
[
10,
21,
28745
],
[
28745,
60,
1191
]
],
[
[
10,
24,
63
],
[
63,
24,
1191
]
],
[
[
10,
24,
148
],
[
148,
63... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy peripheral"
],
[
"Neuropathy peripheral",
"{u} (Side... | Dapsone (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Levodopa (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when ta... |
DB00285 | DB04837 | 1,100 | 649 | [
"DDInter1927",
"DDInter407"
] | Venlafaxine | Clofedanol | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1100,
24,
649
]
],
[
[
1100,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1100,
24,
832
],
[
832,
40,
649
]
],
[
[
1100,
63,
701
],
[
701,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Tripelenn... |
DB06643 | DB12267 | 1,136 | 1,476 | [
"DDInter500",
"DDInter233"
] | Denosumab | Brigatinib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1136,
24,
1476
]
],
[
[
1136,
63,
168
],
[
168,
23,
1476
]
],
[
[
1136,
63,
629
],
[
629,
24,
1476
]
],
[
[
1136,
24,
951
],
[
951,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus m... |
DB01122 | DB01285 | 158 | 708 | [
"DDInter61",
"DDInter445"
] | Ambenonium | Corticotropin | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
158,
24,
708
]
],
[
[
158,
24,
1011
],
[
1011,
64,
708
]
],
[
[
158,
6,
10558
],
[
10558,
45,
61
],
[
61,
24,
708
]
],
[
[
158,
... | [
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[... | Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Corticotropin
Ambenonium (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Edrophonium (Compound) and Edrophonium may cause a moder... |
DB04868 | DB08930 | 478 | 1,459 | [
"DDInter1293",
"DDInter582"
] | Nilotinib | Dolutegravir | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
478,
23,
1459
]
],
[
[
478,
6,
15705
],
[
15705,
45,
1459
]
],
[
[
478,
21,
28698
],
[
28698,
60,
1459
]
],
[
[
478,
63,
353
],
[
353,... | [
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Nilotinib",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nilotinib (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Dolutegravir (Compound)
Nilotinib (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dolutegravir (Compound)
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Gri... |
DB08864 | DB08881 | 786 | 868 | [
"DDInter1595",
"DDInter1925"
] | Rilpivirine | Vemurafenib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
786,
25,
868
]
],
[
[
786,
6,
8374
],
[
8374,
45,
868
]
],
[
[
786,
21,
28643
],
[
28643,
60,
868
]
],
[
[
786,
62,
112
],
[
112,
... | [
[
[
"Rilpivirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rilpivirine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Rilpivirine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rilpivirine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Vemurafenib (Compound)
Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole an... |
DB00308 | DB06663 | 347 | 1,154 | [
"DDInter901",
"DDInter1398"
] | Ibutilide | Pasireotide | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
347,
25,
1154
]
],
[
[
347,
21,
29024
],
[
29024,
60,
1154
]
],
[
[
347,
23,
112
],
[
112,
23,
1154
]
],
[
[
347,
25,
1662
],
[
1662,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} ... | Ibutilide (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Pasireotide (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with ... |
DB00220 | DB11979 | 798 | 1,320 | [
"DDInter1276",
"DDInter625"
] | Nelfinavir | Elagolix | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
798,
25,
1320
]
],
[
[
798,
63,
168
],
[
168,
23,
1320
]
],
[
[
798,
24,
608
],
[
608,
23,
1320
]
],
[
[
798,
25,
1297
],
[
1297,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine m... |
DB01024 | DB01327 | 1,096 | 1,227 | [
"DDInter1252",
"DDInter314"
] | Mycophenolic acid | Cefazolin | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. | Moderate | 1 | [
[
[
1096,
24,
1227
]
],
[
[
1096,
24,
1124
],
[
1124,
40,
1227
]
],
[
[
1096,
63,
1087
],
[
1087,
40,
1227
]
],
[
[
1096,
63,
277
],
[
277... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefazolin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefazolin (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefotaxime and Cefotaxime (Compound) resembles Cefazol... |
DB00366 | DB09118 | 1,594 | 1,580 | [
"DDInter600",
"DDInter1711"
] | Doxylamine | Stiripentol | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1594,
24,
1580
]
],
[
[
1594,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
1594,
24,
1609
],
[
1609,
63,
1580
]
],
[
[
1594,
35,
128
],
[
128... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pe... |
DB04865 | DB05239 | 4 | 866 | [
"DDInter1335",
"DDInter425"
] | Omacetaxine mepesuccinate | Cobimetinib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
4,
24,
866
]
],
[
[
4,
63,
888
],
[
888,
24,
866
]
],
[
[
4,
24,
496
],
[
496,
63,
866
]
],
[
[
4,
25,
1618
],
[
1618,
63,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when tak... |
DB06043 | DB08895 | 1,644 | 976 | [
"DDInter1328",
"DDInter1825"
] | Olaratumab | Tofacitinib | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1644,
25,
976
]
],
[
[
1644,
24,
200
],
[
200,
63,
976
]
],
[
[
1644,
24,
1430
],
[
1430,
24,
976
]
],
[
[
1644,
25,
1011
],
[
1011,
... | [
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Can... | Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleuc... |
DB00819 | DB09425 | 471 | 1,273 | [
"DDInter15",
"DDInter919"
] | Acetazolamide | Indium In-111 pentetate | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column. | Moderate | 1 | [
[
[
471,
24,
1273
]
],
[
[
471,
1,
997
],
[
997,
24,
1273
]
],
[
[
471,
5,
11595
],
[
11595,
44,
997
],
[
997,
24,
1273
]
],
[
[
471,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 pentetate"
]
],
[
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
],
[
"Methazolamide",
... | Acetazolamide (Compound) resembles Methazolamide (Compound) and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 pentetate
Acetazolamide (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Methazolamide (Compound) and Methazolamide may cau... |
DB01132 | DB01259 | 1,130 | 392 | [
"DDInter1472",
"DDInter1024"
] | Pioglitazone | Lapatinib | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1130,
24,
392
]
],
[
[
1130,
6,
8374
],
[
8374,
45,
392
]
],
[
[
1130,
21,
29429
],
[
29429,
60,
392
]
],
[
[
1130,
24,
637
],
[
637,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Pioglitazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Pioglitazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Pioglitazone (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Asp... |
DB09065 | DB12001 | 760 | 564 | [
"DDInter424",
"DDInter7"
] | Cobicistat | Abemaciclib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
760,
25,
564
]
],
[
[
760,
63,
868
],
[
868,
24,
564
]
],
[
[
760,
64,
392
],
[
392,
24,
564
]
],
[
[
760,
25,
982
],
[
982,
63,... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafe... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Cobicistat may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause... |
DB08881 | DB12095 | 868 | 179 | [
"DDInter1925",
"DDInter1760"
] | Vemurafenib | Telotristat ethyl | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
868,
24,
179
]
],
[
[
868,
64,
79
],
[
79,
24,
179
]
],
[
[
868,
63,
310
],
[
310,
24,
179
]
],
[
[
868,
24,
214
],
[
214,
24,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"So... | Vemurafenib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel m... |
DB00595 | DB01024 | 1,545 | 1,096 | [
"DDInter1374",
"DDInter1252"
] | Oxytetracycline | Mycophenolic acid | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
1545,
24,
1096
]
],
[
[
1545,
24,
955
],
[
955,
1,
1096
]
],
[
[
1545,
24,
1193
],
[
1193,
62,
1096
]
],
[
[
1545,
63,
1031
],
[
1031,... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenol... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc glucon... |
DB09481 | DB12035 | 460 | 943 | [
"DDInter1113",
"DDInter1641"
] | Magnesium carbonate | Sarecycline | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
460,
24,
943
]
],
[
[
460,
63,
1596
],
[
1596,
24,
943
]
],
[
[
460,
24,
428
],
[
428,
63,
943
]
],
[
[
460,
63,
1596
],
[
1596,
... | [
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
... | Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumara... |
DB00377 | DB00938 | 1,494 | 455 | [
"DDInter1382",
"DDInter1635"
] | Palonosetron | Salmeterol | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1494,
24,
455
]
],
[
[
1494,
24,
688
],
[
688,
63,
455
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
455
]
],
[
[
1494,
21,
29024
],
[
29024,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Palonosetron (... |
DB00529 | DB00798 | 789 | 1,132 | [
"DDInter779",
"DDInter815"
] | Foscarnet | Gentamicin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Major | 2 | [
[
[
789,
25,
1132
]
],
[
[
789,
6,
10612
],
[
10612,
45,
1132
]
],
[
[
789,
21,
28703
],
[
28703,
60,
1132
]
],
[
[
789,
25,
361
],
[
361,... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
]
],
[
[
"Foscarnet",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Gentami... | Foscarnet (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Gentamicin (Compound)
Foscarnet (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gentamicin (Compound)
Foscarnet may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a mod... |
DB00637 | DB08903 | 1,557 | 996 | [
"DDInter128",
"DDInter170"
] | Astemizole | Bedaquiline | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1557,
25,
996
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1557,
23,
112
],
[
112,
23,
996
]
],
[
[
1557,
63,
355
],
[
355,
... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaqu... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Astemizole may... |
DB01232 | DB11703 | 1,327 | 405 | [
"DDInter1640",
"DDInter9"
] | Saquinavir | Acalabrutinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1327,
25,
405
]
],
[
[
1327,
63,
1051
],
[
1051,
24,
405
]
],
[
[
1327,
25,
951
],
[
951,
24,
405
]
],
[
[
1327,
25,
982
],
[
982,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Saquinavir may lead to a major life threatening interaction when taken with Palbociclib and Pal... |
DB00480 | DB00783 | 1,668 | 1,438 | [
"DDInter1035",
"DDInter679"
] | Lenalidomide | Estradiol | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Major | 2 | [
[
[
1668,
25,
1438
]
],
[
[
1668,
25,
35
],
[
35,
40,
1438
]
],
[
[
1668,
64,
380
],
[
380,
40,
1438
]
],
[
[
1668,
6,
4973
],
[
4973,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Estradiol"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u... | Lenalidomide may lead to a major life threatening interaction when taken with Quinestrol and Quinestrol (Compound) resembles Estradiol (Compound)
Lenalidomide may lead to a major life threatening interaction when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estradiol (Compound)
Lenalido... |
DB00307 | DB08867 | 1,101 | 807 | [
"DDInter202",
"DDInter1897"
] | Bexarotene | Ulipristal | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
1101,
24,
807
]
],
[
[
1101,
24,
1135
],
[
1135,
62,
807
]
],
[
[
1101,
62,
600
],
[
600,
23,
807
]
],
[
[
1101,
23,
609
],
[
609,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole... |
DB00467 | DB01181 | 1,467 | 1,532 | [
"DDInter644",
"DDInter906"
] | Enoxacin | Ifosfamide | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Minor | 0 | [
[
[
1467,
23,
1532
]
],
[
[
1467,
7,
5415
],
[
5415,
46,
1532
]
],
[
[
1467,
40,
1299
],
[
1299,
23,
1532
]
],
[
[
1467,
1,
956
],
[
956,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
]
],
[
[
"Enoxacin",
"{u} (Compound) upregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (Compo... | Enoxacin (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound)
Enoxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Enoxacin (Compound) resembles Norfloxacin (Compound) a... |
DB01320 | DB06410 | 651 | 1,196 | [
"DDInter783",
"DDInter595"
] | Fosphenytoin | Doxercalciferol | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
651,
24,
1196
]
],
[
[
651,
40,
362
],
[
362,
24,
1196
]
],
[
[
651,
24,
1619
],
[
1619,
63,
1196
]
],
[
[
651,
25,
1017
],
[
1017,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a ... | Fosphenytoin (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that ... |
DB06317 | DB15965 | 1,626 | 1,330 | [
"DDInter630",
"DDInter1270"
] | Elotuzumab | Naxitamab | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
1626,
24,
1330
]
],
[
[
1626,
63,
14
],
[
14,
24,
1330
]
],
[
[
1626,
24,
259
],
[
259,
24,
1330
]
],
[
[
1626,
25,
375
],
[
375,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Ril... |
DB00346 | DB00836 | 472 | 543 | [
"DDInter44",
"DDInter1088"
] | Alfuzosin | Loperamide | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
472,
24,
543
]
],
[
[
472,
24,
888
],
[
888,
24,
543
]
],
[
[
472,
6,
8374
],
[
8374,
45,
543
]
],
[
[
472,
21,
28722
],
[
28722,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loperamide (Compound)
Alfuzosin (Compound) c... |
DB05679 | DB14811 | 1,683 | 385 | [
"DDInter1907",
"DDInter979"
] | Ustekinumab | Isatuximab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
1683,
24,
385
]
],
[
[
1683,
24,
1362
],
[
1362,
24,
385
]
],
[
[
1683,
63,
377
],
[
377,
24,
385
]
],
[
[
1683,
25,
908
],
[
908,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin... |
DB06603 | DB06636 | 39 | 1,623 | [
"DDInter1387",
"DDInter980"
] | Panobinostat | Isavuconazonium | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
39,
24,
1623
]
],
[
[
39,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
39,
64,
1557
],
[
1557,
24,
1623
]
],
[
[
39,
25,
1593
],
[
1593,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Panobinostat may lead to a major life threatening interaction when taken with Astemizole and Astemizole may c... |
DB00461 | DB09156 | 598 | 777 | [
"DDInter1254",
"DDInter964"
] | Nabumetone | Iopromide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
598,
25,
777
]
],
[
[
598,
24,
372
],
[
372,
25,
777
]
],
[
[
598,
25,
663
],
[
663,
25,
777
]
],
[
[
598,
63,
1645
],
[
1645,
2... | [
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabin... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iopromide
Nabumetone may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may lead to a major ... |
DB00191 | DB01001 | 73 | 688 | [
"DDInter1447",
"DDInter1632"
] | Phentermine | Salbutamol | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
73,
24,
688
]
],
[
[
73,
24,
874
],
[
874,
24,
688
]
],
[
[
73,
24,
1148
],
[
1148,
63,
688
]
],
[
[
73,
21,
28714
],
[
28714,
6... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and ... |
DB01211 | DB08886 | 609 | 637 | [
"DDInter393",
"DDInter126"
] | Clarithromycin | Asparaginase Erwinia chrysanthemi | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
609,
24,
637
]
],
[
[
609,
25,
392
],
[
392,
24,
637
]
],
[
[
609,
63,
167
],
[
167,
24,
637
]
],
[
[
609,
24,
5
],
[
5,
24,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
... | Clarithromycin may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Hydroco... |
DB06335 | DB09082 | 761 | 659 | [
"DDInter1646",
"DDInter1934"
] | Saxagliptin | Vilanterol | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
761,
24,
659
]
],
[
[
761,
63,
1220
],
[
1220,
23,
659
]
],
[
[
761,
24,
1296
],
[
1296,
63,
659
]
],
[
[
761,
63,
323
],
[
323,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglude... |
DB01075 | DB01158 | 1,376 | 1,286 | [
"DDInter569",
"DDInter229"
] | Diphenhydramine | Bretylium | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of vol... | Moderate | 1 | [
[
[
1376,
24,
1286
]
],
[
[
1376,
21,
29017
],
[
29017,
60,
1286
]
],
[
[
1376,
21,
29017
],
[
29017,
60,
61
],
[
61,
40,
1286
]
],
[
[
13... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bretylium"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating increased"
],
[
"Sweating increased",
... | Diphenhydramine (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Bretylium (Compound)
Diphenhydramine (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Edrophonium (Compound) and Edrophonium (Compound) resembles Brety... |
DB01236 | DB09020 | 679 | 28 | [
"DDInter1664",
"DDInter212"
] | Sevoflurane | Bisacodyl | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
679,
24,
28
]
],
[
[
679,
21,
28666
],
[
28666,
60,
28
]
],
[
[
679,
24,
823
],
[
823,
63,
28
]
],
[
[
679,
25,
982
],
[
982,
63... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Sevoflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
... | Sevoflurane (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exac... |
DB00570 | DB06372 | 147 | 259 | [
"DDInter1936",
"DDInter1594"
] | Vinblastine | Rilonacept | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
147,
24,
259
]
],
[
[
147,
63,
1461
],
[
1461,
23,
259
]
],
[
[
147,
24,
0
],
[
0,
24,
259
]
],
[
[
147,
24,
1619
],
[
1619,
63,... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactin... |
DB06210 | DB12130 | 72 | 1,017 | [
"DDInter631",
"DDInter1094"
] | Eltrombopag | Lorlatinib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
72,
24,
1017
]
],
[
[
72,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
72,
63,
14
],
[
14,
24,
1017
]
],
[
[
72,
24,
1491
],
[
1491,
24... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Ro... |
DB00544 | DB08904 | 970 | 375 | [
"DDInter757",
"DDInter342"
] | Fluorouracil | Certolizumab pegol | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
970,
25,
375
]
],
[
[
970,
63,
1461
],
[
1461,
23,
375
]
],
[
[
970,
24,
200
],
[
200,
63,
375
]
],
[
[
970,
63,
66
],
[
66,
24,... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Candida albic... |
DB08875 | DB14975 | 1,618 | 988 | [
"DDInter262",
"DDInter1949"
] | Cabozantinib | Voxelotor | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
1618,
24,
988
]
],
[
[
1618,
63,
222
],
[
222,
23,
988
]
],
[
[
1618,
63,
629
],
[
629,
24,
988
]
],
[
[
1618,
25,
985
],
[
985,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Siro... |
DB00446 | DB01004 | 597 | 563 | [
"DDInter351",
"DDInter806"
] | Chloramphenicol | Ganciclovir | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
597,
24,
563
]
],
[
[
597,
24,
248
],
[
248,
40,
563
]
],
[
[
597,
6,
10612
],
[
10612,
45,
563
]
],
[
[
597,
18,
10375
],
[
10375,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Chloramphenicol (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ganciclovir (Compound)
Chloramphenicol (Compound) downregulates RPS... |
DB00844 | DB06209 | 314 | 256 | [
"DDInter1257",
"DDInter1508"
] | Nalbuphine | Prasugrel | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
314,
24,
256
]
],
[
[
314,
21,
28681
],
[
28681,
60,
256
]
],
[
[
314,
63,
752
],
[
752,
23,
256
]
],
[
[
314,
25,
593
],
[
593,
... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Nalbuphine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Ef... | Nalbuphine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken w... |
DB00853 | DB14783 | 1,686 | 287 | [
"DDInter1762",
"DDInter574"
] | Temozolomide | Diroximel fumarate | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1686,
24,
287
]
],
[
[
1686,
63,
1560
],
[
1560,
24,
287
]
],
[
[
1686,
24,
384
],
[
384,
24,
287
]
],
[
[
1686,
25,
770
],
[
770,
... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Idela... |
DB00860 | DB01174 | 891 | 697 | [
"DDInter1513",
"DDInter1442"
] | Prednisolone | Phenobarbital | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
891,
24,
697
]
],
[
[
891,
63,
759
],
[
759,
1,
697
]
],
[
[
891,
63,
536
],
[
536,
40,
697
]
],
[
[
891,
6,
8717
],
[
8717,
45,... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Phenobarbital... |
DB00637 | DB01224 | 1,557 | 623 | [
"DDInter128",
"DDInter1553"
] | Astemizole | Quetiapine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1557,
24,
623
]
],
[
[
1557,
24,
827
],
[
827,
1,
623
]
],
[
[
1557,
25,
851
],
[
851,
1,
623
]
],
[
[
1557,
64,
695
],
[
695,
1... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Astemizole may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Astemizole may le... |
DB01023 | DB08865 | 409 | 1,593 | [
"DDInter716",
"DDInter448"
] | Felodipine | Crizotinib | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
409,
24,
1593
]
],
[
[
409,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
409,
7,
6952
],
[
6952,
46,
1593
]
],
[
[
409,
21,
29093
],
[
29093,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Felodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Felodipine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Crizotinib (Compound)
Felodipine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Felodipi... |
DB00087 | DB06650 | 599 | 1,500 | [
"DDInter41",
"DDInter1324"
] | Alemtuzumab | Ofatumumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Moderate | 1 | [
[
[
599,
24,
1500
]
],
[
[
599,
24,
270
],
[
270,
63,
1500
]
],
[
[
599,
24,
869
],
[
869,
24,
1500
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Top... |
DB00008 | DB11640 | 491 | 1,267 | [
"DDInter1407",
"DDInter64"
] | Peginterferon alfa-2a | Amifampridine | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
491,
24,
1267
]
],
[
[
491,
24,
1613
],
[
1613,
24,
1267
]
],
[
[
491,
25,
497
],
[
497,
25,
1267
]
],
[
[
491,
24,
1613
],
[
1613,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pe... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Peginterferon alfa-2a may lead to a major life threatening interaction when ... |
DB00776 | DB05676 | 1,335 | 1,513 | [
"DDInter1360",
"DDInter111"
] | Oxcarbazepine | Apremilast | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Moderate | 1 | [
[
[
1335,
24,
1513
]
],
[
[
1335,
40,
307
],
[
307,
23,
1513
]
],
[
[
1335,
24,
1421
],
[
1421,
63,
1513
]
],
[
[
1335,
62,
1101
],
[
1101... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a min... | Oxcarbazepine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that cou... |
DB00087 | DB01394 | 599 | 1,554 | [
"DDInter41",
"DDInter431"
] | Alemtuzumab | Colchicine | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
599,
24,
1554
]
],
[
[
599,
63,
367
],
[
367,
24,
1554
]
],
[
[
599,
24,
375
],
[
375,
63,
1554
]
],
[
[
599,
24,
168
],
[
168,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Colchicine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00564 | DB01229 | 1,236 | 973 | [
"DDInter293",
"DDInter1378"
] | Carbamazepine | Paclitaxel (protein-bound) | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1236,
24,
973
]
],
[
[
1236,
24,
310
],
[
310,
63,
973
]
],
[
[
1236,
6,
7524
],
[
7524,
45,
973
]
],
[
[
1236,
18,
10375
],
[
10375,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Ca... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.